The authors hypothesized that IL-27 might be produced by microenvironment cells as a response to neoplastic cells to reduce Th2 immunity, typically associated with CTCL progression [129]. The gene discussed is IL27; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.